Robert Orlowski, Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared on X:
“Myeloma Paper of the Day:
Dara-VRd, upfront ASCT and len maintenance for NDMM shows 4-year PFS rate of 71% and trend towards inferior PFS among patients w/ R-ISS stage III disease & those classified as high-risk disease by 2025 IMS/IMWG criteria.”
Title: Daratumumab, Bortezomib, Lenalidomide and Dexamethasone, Upfront Autologous Transplant and Lenalidomide Maintenance for Newly Diagnosed Multiple Myeloma
Authors: Oren Pasvolsky, Muhammad Bilal Abid, Denái R. Milton, Mark R. Tanner, Sohaib Irfan, Qaiser Bashir, Samer Srour, Neeraj Saini, Paul Lin, Jeremy Ramdial, Yago Nieto, Guilin Tang, Asad A. Haider, Yosra Aljawai, Partow Kebriaei, Krina K. Patel, Christine Ye, Sheeba K. Thomas, Robert Z. Orlowski, Richard E. Champlin, Muzaffar H. Qazilbash
You can read the full article on Transplantation and Cellular Therapy.
You can find other articles featuring Robert Orlowski on OncoDaily.
